Matthew C•••

About

On the record

Experienced in engineering and sales with an emphasis on biotechnology. If your work involves the charge-based characterization of biologics, you may be noticing. → Increased scrutiny for post-translation modifications (PTMs) → Magnified differences between icIEF and IEX → Highly heterogeneous new modalities → Carrier ampholyte lot-to-lot variability → Instrument discontinuation If you're familiar with one or more of these challenges and they are complicating method development, BLA submission, or batch release, let's talk. We've been developing icIEF technologies for the last 15 years, and in many ways, have set a new standard for characterization, building confidence in charge stability, and helping biologics get over the finish line faster.